Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.9730
-0.0170 (-1.72%)
At close: Aug 29, 2025, 4:00 PM
0.9654
-0.0076 (-0.78%)
After-hours: Aug 29, 2025, 7:59 PM EDT
Invivyd Revenue
Invivyd had revenue of $11.79M in the quarter ending June 30, 2025, with 420.58% growth. This brings the company's revenue in the last twelve months to $46.21M, up 1,941.08% year-over-year. In the year 2024, Invivyd had annual revenue of $25.38M.
Revenue (ttm)
$46.21M
Revenue Growth
+1,941.08%
P/S Ratio
2.52
Revenue / Employee
$462,100
Employees
100
Market Cap
189.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IVVD News
- 3 days ago - Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless Of Trump Admin Anti-Vaccine Actions - Seeking Alpha
- 5 days ago - Invivyd to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 10 days ago - Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Shares - GlobeNewsWire
- 11 days ago - Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 12 days ago - Invivyd Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 14 days ago - Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”) - GlobeNewsWire
- 18 days ago - Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 18 days ago - Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 - GlobeNewsWire